logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Trovagene's News Is Encouraging

About Trovagene Trovagene ( TROV )  is still a clinical-stage company.  The p recision cancer medicine approach is practicing what it preaches right now in order to develop drugs that target cell division (mitosis) for: leukemias, lymphomas and solid tumor...

Read More

April 24, 2019

0

Trick or Trade?

The Misleading Market? The biotech stocks continue to begin their daily trading relying on opinionated articles implanted by bloggers on the Internet rather than on the firms’ voiced news.  It is unfortunate that we continue to observe many investors incapable...

Read More

April 26, 2019

0

After being approved for Eczema, Regeneron's and Sanofi's product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.

In two pivotal Phase 3 placebo-controlled trials Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) drug,  Dupixent® (dupilumab), demonstrated a significant reduction in nasal polyp size, nasal congestion’s severity and the need for systemic corticosteroids and/or surgery. Both trials were evaluating Dupixent® (dupilumab) in...

Read More

October 16, 2018

0

Exelixis is Still a Favorite

EXELIXIS Being called overvalued by one analyst does not mean that Exelixis (EXEL) is, indeed, overvalued. We believe it is not and that’s why we decided to accumulate the stock on any weaknesses in EXEL. We do not intend to...

Read More

September 22, 2017

0

The FDA Approval of Regeneron/Sanofi Praluent Is A Big Deal. Will the FDA Approve Nabriva Therapeutics’ Antibiotic Contepo Today?

Praluent's Approval Is a Big Deal The approval of the Regeneron / Sanofi s upplemental biological license application ( sBLA ) aimed at updating Praluent’s (alirocumab)  prescribing information is, indeed, a big deal. Proven life-saving benefits are confirmed. Comprising reducing...

Read More

April 30, 2019

0

Why VTV Therapeutics' stock added over 48% to its price before trading hours today

VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today. The news that some believe is behind investors’ enthusiasm is the firm’s announcement that it will deliver two presentations at the 11 th clinical trials on Alzheimer’s Disease...

Read More

October 17, 2018

0

Vertex Has Good News and Exelixis Is Reinforcing Its Outperformance

Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children Good news for Vertex ( VRTX ) product  Kalydeco ®  (ivacaftor) is the first cystic fibrosis ( CF ) product to be prescribed for children ages six months to less than...

Read More

May 2, 2019

0

Why Portola's stock decline

Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed to put two FDA-approved products on the market. They are: Bevyxxa ®  (betrixaban):  The first and only once-daily oral Factor Xa inhibitor, for the prevention...

Read More

October 17, 2018

0

Will NewLink Genetics' IDO Inhibitor Improve the Efficacy of AstraZeneca's Checkpoint Inhibitor in Treating Pancreatic Cancer?

AstraZeneca’s (AZN) checkpoint PD-L1 inhibitor Imfinzi and NewLink Genetics’ (NLNK) IDO inhibitor indoximod will be combined and tested in Phase 2 randomized, placebo-controlled clinical trials together with the standard of care chemotherapy treatment for metastatic pancreatic cancer . AstraZeneca and...

Read More

September 28, 2017

0

A Firm That Defied the Fierce Unwarranted Bear Market Day

Why GW Pharmaceuticals Survived the Bear Market Day The DOW Today Sinking for disputed and unfathomed reasons; watching and listening to analysts with antagonistic opinions on the TV screen; the stock market has taken down with it all the DOW...

Read More

May 7, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 59
  • 60
  • 61
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy